Achieving efficient pricing of pharmaceuticals between and within countries is a complex conceptually and critical a policy challenge. The optimal price that maximises social welfare must achieve two objectives: static efficiency, i.e. optimal use of existing products, and dynamic efficiency, i.e. optimal investment in R&D. This presentation reviews recent thinking on the core challenges.